Last reviewed · How we verify

NCT00751218

A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (Study P03735)

Completed Phase 4 Last updated 15 August 2024
What this trial tests

Phase 4 trial testing desloratadine in Urticaria in 174 participants. Completed in 24 May 2005.

Timeline
6 May 2004
Primary endpoint
24 May 2005
24 May 2005

Quick facts

Lead sponsorOrganon and Co
PhasePhase 4
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment174
Start date6 May 2004
Primary completion24 May 2005
Estimated completion24 May 2005

Drugs / interventions tested

Conditions studied

Sponsor

Organon and Co — full company profile →

Who can join

Adults 12 to 70, any sex, with Urticaria. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (cetirizine) and a placebo control to evaluate desloratadine 5 mg once daily during a 28-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. H1-antihistamines for chronic spontaneous urticaria.
    Sharma M, Bennett C, Cohen SN, Carter B. · · 2014 · cited 22× · PMID 25397904 · DOI 10.1002/14651858.cd006137.pub2

Verify or expand the search:

Other trials of desloratadine

Trials testing the same drug.

Other Organon and Co trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00751218.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing